EBV DNAemia After Solid Organ Transplant: Risk Stratification, Monitoring, Treatment and Progression to Post-Transplant Lymphoproliferative Disorder

Epstein–Barr virus (EBV) is a nearly ubiquitous oncogenic virus that drives the development of post-transplant lymphoproliferative disorder (PTLD) in solid organ-transplant (SOT) recipients through B-lymphocyte infection and disruption of normal apoptotic and immune-surveillance pathways. This review synthesizes current evidence on the relationship between EBV DNAemia and PTLD, demonstrating that elevated whole blood or plasma EBV viral loads may precede and help identify patients at increased risk of EBV+ PTLD, though testing methodology and timing remain unstandardized across studies. EBV DNAemia is associated with increased risk of PTLD, particularly in high-risk serostatus and heavily immunosuppressed recipients. However, differences in specimen types, assay methodologies, and intervention thresholds currently limit predictive precision and standardization of preemptive management. Frontline management of EBV DNAemia follows a stepwise approach beginning with reduced immunosuppression, escalating to rituximab and sequential chemoimmunotherapy as needed if PTLD develops. For relapsed or refractory EBV-positive disease, emerging EBV-directed cellular therapies show meaningful survival benefit over historical outcomes. Novel biomarkers for EBV may include soluble ZEBRA protein assessment, EBV DNA methylation, and LMP1 mutation status, in addition to CMV DNAemia. There remains an urgent unmet need for standardized, prospective, multicenter studies to define optimal EBV monitoring strategies and guide preemptive intervention in this high-risk population.

Authors

Institutions

Publication Details

Journal
Viruses
Published
2026-11-17
DOI
https://doi.org/10.3390/v18111276
Primary Topic
Viral-associated cancers and disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

EBV DNAemia After Solid Organ Transplant: Risk Stratification, Monitoring, Treatment and Progression to Post-Transplant Lymphoproliferative Disorder

Bradley M. Haverkos, Cassandra Duarte
1 links
Viruses
Viral-associated cancers and disorders
article

EBV DNAemia After Solid Organ Transplant: Risk Stratification, Monitoring, Treatment and Progression to Post-Transplant Lymphoproliferative Disorder

Bradley M. Haverkos, Cassandra Duarte
article en

Abstract

Epstein–Barr virus (EBV) is a nearly ubiquitous oncogenic virus that drives the development of post-transplant lymphoproliferative disorder (PTLD) in solid organ-transplant (SOT) recipients through B-lymphocyte infection and disruption of normal apoptotic and immune-surveillance pathways. This review synthesizes current evidence on the relationship between EBV DNAemia and PTLD, demonstrating that elevated whole blood or plasma EBV viral loads may precede and help identify patients at increased risk of EBV+ PTLD, though testing methodology and timing remain unstandardized across studies. EBV DNAemia is associated with increased risk of PTLD, particularly in high-risk serostatus and heavily immunosuppressed recipients. However, differences in specimen types, assay methodologies, and intervention thresholds currently limit predictive precision and standardization of preemptive management. Frontline management of EBV DNAemia follows a stepwise approach beginning with reduced immunosuppression, escalating to rituximab and sequential chemoimmunotherapy as needed if PTLD develops. For relapsed or refractory EBV-positive disease, emerging EBV-directed cellular therapies show meaningful survival benefit over historical outcomes. Novel biomarkers for EBV may include soluble ZEBRA protein assessment, EBV DNA methylation, and LMP1 mutation status, in addition to CMV DNAemia. There remains an urgent unmet need for standardized, prospective, multicenter studies to define optimal EBV monitoring strategies and guide preemptive intervention in this high-risk population.

VirusesVol. 18(11)
University of Colorado System (US), University of Colorado Anschutz Medical Campus (US), University of Colorado Denver (US)
Good health and well-being
Viral-associated cancers and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon